Companies › Anova Innovation
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ANO31905 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Pancreatic Cancer | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07444541 | ANO31905 | Phase 1 | Pancreatic Cancer | Oncology | Aug 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.